HRS-9231 + Gadobutrol
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions
Conditions
For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions
Trial Timeline
Dec 1, 2024 → Apr 1, 2025
NCT ID
NCT06731829About HRS-9231 + Gadobutrol
HRS-9231 + Gadobutrol is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06731829. Target conditions include For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06731829 | Phase 2 | Recruiting |